A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Main Inclusion/Exclusion:
- ECOG 0 to 1
- Hemoglobin (for monotherapy patients only) is greater than or equal to 8.0 g/dL
- Hemoglobin (for combination patients only) is greater than or equal to 9.0 g/dL
- Stable/treated brain metastases is acceptable.
Contact: cajwciclinicaltrials@providence.org